Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S. Food and …

cemiplimab
metastasis
acquired immunodeficiency syndrome (aids)
lymphoma
cancer
  • 0 views
  • 19 Feb, 2024
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Giving cemiplimab before surgery may improve risk of the cancer returning in patients with high risk cutaneous squamous cell cancer.

monoclonal antibodies
follicle stimulating hormone
oophorectomy
hypothyroidism
carcinoma
  • 0 views
  • 19 Feb, 2024
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

systemic therapy
gonadotropin
antibiotics
HIV Infection
carcinoma
  • 2 views
  • 19 Feb, 2024